The Ensign Group (ENSG) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Achieved record Q2 2024 results with consolidated revenue of $1.04B, up 12.5% year-over-year, and strong growth in occupancy and skilled mix days, particularly in managed care populations.
Net income rose 11% to $71M, with GAAP diluted EPS of $1.22 (up 8.9%) and adjusted EPS of $1.32 (up 13.8%).
Expanded portfolio to 312 operations across 14 states, adding 15 new operations and multiple real estate assets, including expansion into Tennessee.
Lower employee turnover for the 11th consecutive quarter and reduced staffing agency usage for the 6th quarter.
Authorized a new $20M stock repurchase program and maintained a quarterly dividend of $0.06 per share, marking 21 consecutive years of annual increases.
Financial highlights
Q2 2024 consolidated revenue: $1.04B (up 12.5% YoY); skilled services revenue: $991.3M (up 12.1% YoY).
Q2 2024 GAAP net income: $71M; adjusted net income: $76.4M (up 15.3% YoY).
Q2 2024 adjusted EBITDA: $117.2M; adjusted EBITDAR: $170.5M.
Cash and cash equivalents at June 30, 2024: $477.3M; available credit: $573.1M.
Paid a quarterly cash dividend of $0.06 per share.
Outlook and guidance
2024 annual revenue guidance raised to $4.20B–$4.22B; diluted EPS guidance increased to $5.38–$5.50.
Midpoint of 2024 EPS guidance is 14% above 2023 and 31% above 2022.
Guidance based on 58.5M diluted shares, 25% tax rate, and includes closed and expected 2024 acquisitions.
Management expects continued growth through acquisitions and operational improvements, with a focus on increasing occupancy and skilled mix.
Q4 expected to be seasonally stronger, with margins consistent with historical trends.
Latest events from The Ensign Group
- Strong growth, robust acquisitions, and proactive regulatory management drive future upside.ENSG
Oppenheimer 36th Annual Healthcare MedTech & Services Conference19 Mar 2026 - Record revenue, earnings, and occupancy drive double-digit FY26 growth outlook.ENSG
Q4 20256 Feb 2026 - Q3 revenue up 15%, net income up 22.8%, and guidance raised amid record occupancy and expansion.ENSG
Q3 20245 Feb 2026 - Growth is fueled by leadership, local empowerment, and disciplined acquisitions amid a stable regulatory outlook.ENSG
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Record 2024 results and strong 2025 outlook driven by growth, acquisitions, and financial strength.ENSG
Q4 202426 Dec 2025 - Q1 2025 revenue up 16.1%, net income up 16.6%, and 2025 guidance raised after record growth.ENSG
Q1 202522 Dec 2025 - Record 2024 results, strong governance, and expanded ESG initiatives highlighted for 2025 meeting.ENSG
Proxy Filing2 Dec 2025 - Director elections, auditor ratification, and incentive plan amendment up for shareholder vote.ENSG
Proxy Filing2 Dec 2025 - Growth continues through acquisitions, innovation, and strategic real estate partnerships.ENSG
RBC Capital Markets Global Healthcare Conference 202524 Nov 2025